Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Skye Bioscience Inc | SKYE | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 12.00 | 03:09:57 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 12.00 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 10.85 - 17.6473 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 12.00 | USD |
Skye Bioscience Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 336.81M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Skye Bioscience News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/19/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 5/17/2024 | 15:27 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 5/10/2024 | 15:19 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 5/10/2024 | 15:17 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 5/10/2024 | 15:02 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SKYE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.55 | 13.44 | 11.2401 | 12.23 | 62,458 | 0.45 | 3.90% |
| 1 Month | 15.50 | 15.5994 | 10.85 | 12.65 | 54,078 | -3.50 | -22.58% |
| 3 Months | 13.50 | 17.6473 | 10.85 | 13.75 | 63,244 | -1.50 | -11.11% |
| 6 Months | 13.50 | 17.6473 | 10.85 | 13.75 | 63,244 | -1.50 | -11.11% |
| 1 Year | 13.50 | 17.6473 | 10.85 | 13.75 | 63,244 | -1.50 | -11.11% |
| 3 Years | 13.50 | 17.6473 | 10.85 | 13.75 | 63,244 | -1.50 | -11.11% |
| 5 Years | 13.50 | 17.6473 | 10.85 | 13.75 | 63,244 | -1.50 | -11.11% |
Skye Bioscience Description
| Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease. |
